Dr. Stella Sarraf founded Spinogenix in 2016 to focus on developing novel neuroregenerative therapeutics. She brings a blend of large pharmaceutical operational expertise, venture investment background & entrepreneurship to Spinogenix. Dr. Sarraf is viewed as a visionary with a deep understanding of “cradle to grave” and the necessary components to achieve success from product concept…
Dr. Peter Vanderlish has been conducting research on synaptic connections and the molecular biology underlying the function of synapses since his graduate work at the University of California, Irvine. During that time, his work helped establish that long-term potentiation (LTP) occurred post-synaptically, that is in more mature dendritic spines. He has been credited with establishing…
Dr. Craig Erickson has been conducting translational research in neurodevelopmental disorders for twenty years. He is the leader of a large translational medicine program at Cincinnati Children’s Hospital Medical Center built to enhance the ability to detect brain target engagement with treatment on an individual patient level. This has enabled Dr. Erickson to, from the…
Dr. Sharron Gargosky (PhD Biochemist) brings to the team a global executional and operational background for clinical development and strategy that spans more than 25 years. She has personally overseen Regulatory, CMC, Non-clinical, Clinical, Early Commercialization, and Medical Affairs in program across more than 15 countries. This work has spanned across therapeutics (IVD, small molecules,…